Loading ...
Sorry, an error occurred while loading the content.

Daily Combination Therapy Better Than Thrice Weekly for Previously Treated HCV Patients

Expand Messages
  • claudine intexas
    Daily Combination Therapy Better than Thrice Weekly for Previously Treated HCV Patients Preliminary results of a study examining daily dosing of combination
    Message 1 of 1 , Jul 31, 2000
    • 0 Attachment
      Daily Combination Therapy Better than Thrice Weekly
      for Previously Treated HCV Patients

      Preliminary results of a study examining daily dosing
      of combination therapy for previously treated chronic
      hepatitis C patients show improved results compared to
      three times a week dosing.

      In a study conducted from September 1997 to March
      1998, 25 HCV patients who had previously relapsed or
      failed to respond to interferon monotherapy were given
      daily doses of interferon afa-2b at 3 million units
      plus ribavirin at 1000-1200 milligrams for twelve
      months.

      "There is no consensus about dose and duration of
      combination therapy," says Zeki Karasu, M.D., lead
      investigator and research fellow, Oklahoma
      Transplantation Institute, Oklahoma City, Oklahoma.
      "When interferon was first approved, it was for three
      times a week, but later, some viral kinetic studies
      showed that daily use of that drug may produce better
      results. Based on this information, we tried daily use
      of these drugs in combination, and we did get better
      results."

      After 12 weeks, 57% (12/21) showed no serum HCV
      (HVC-RNA negative) but 43% (9/21) remained HCV-RNA
      positive. Four of the 25 dropped out of the study. Of
      the ten relapsers to previous interferon monotherapy,
      9 (90%) responded to the regimen in this study. Of the
      11 previous non-responders, 3 (27%) showed HCV RNA
      clearance here.

      The response rate for non-responding or relapsing
      patients is usually quite low, Dr. Karasu says. "Our
      results for daily use of these two drugs show much
      better results."

      At three months, the side effects from daily dosing of
      combination therapy "were comparable to three times a
      week dosing [of combination therapy]" Dr. Karasu says.
      Dose reductions were necessary for 12 patients, mainly
      because of anemia and fatigue. And he notes the need
      for close patient monitoring because of the likelihood
      of these complications from the ribavirin component of
      the combination therapy.

      The study is continuing, but Dr. Karasu noted that
      patients who respond in 3 months of treatment tend to
      have a sustained response. "If the patient doesn't
      respond after three months time, they usually don't
      respond after that."

      Source:
      Wellness Web



      =====
      Claudine
      claudinecrews@...

      __________________________________________________
      Do You Yahoo!?
      Kick off your party with Yahoo! Invites.
      http://invites.yahoo.com/
    Your message has been successfully submitted and would be delivered to recipients shortly.